Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
Blood Adv
; 6(12): 3606-3610, 2022 06 28.
Article
in En
| MEDLINE
| ID: mdl-35271707
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, Mantle-Cell
/
Antineoplastic Agents
Limits:
Adult
/
Humans
Language:
En
Journal:
Blood Adv
Year:
2022
Document type:
Article
Affiliation country:
España
Country of publication:
Estados Unidos